Prothena (FRA:0PT) Current Accrued Expense : €18.8 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Prothena Current Accrued Expense?

Prothena's Current Accrued Expense for the quarter that ended in Mar. 2025 was €18.8 Mil.

Prothena's quarterly Current Accrued Expense increased from Sep. 2024 (€20.9 Mil) to Dec. 2024 (€26.6 Mil) but then declined from Dec. 2024 (€26.6 Mil) to Mar. 2025 (€18.8 Mil).

Prothena's annual Current Accrued Expense increased from Dec. 2022 (€21.2 Mil) to Dec. 2023 (€25.6 Mil) and increased from Dec. 2023 (€25.6 Mil) to Dec. 2024 (€26.6 Mil).

Prothena Current Accrued Expense Historical Data

The historical data trend for Prothena's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Current Accrued Expense Chart

Prothena Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

12.88

13.95

21.20

25.65

26.64

Prothena Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															22.55	23.91	20.91	26.64	18.80

Prothena Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Prothena Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Prothena's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Prothena Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (FRA:0PT) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

PRTA:USA 0Y3M:UK

Address

77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60

Website

https://www.prothena.com

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Prothena Headlines

No Headlines